Intramyocardial gene transfer of vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
Full Text
Reprint PDF

Keywords

collateral development
coronary artery disease
gene therapy
naked plasmid DNA
revascularization
therapeutic angiogenesis

How to Cite

1.
Ojalvo AG, Seralena A, Vispo NS, Silva R, Gonzalez N, Guevara L, Batista JF, Montequin JF, Chaos N, González R, Reima C, Peña Y, Coca M, Perera A, Vazquez R, Puchades Y, Garcia-Osuna T, Dominguez H, Reyes JL, Ali A, Herrera L. Intramyocardial gene transfer of vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. Electron. J. Biotechnol. [Internet]. 2004 Dec. 15 [cited 2024 Sep. 19];7(3):0-. Available from: https://preprints.pucv.cl/index.php/ejbiotechnology/article/view/v7n3-12

Abstract

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen that is angiogenic in vitro and in vivo. Several studies report on gene transfer of VEGF121 to promote angiogenesis in the ischemic myocardium of animals and patients. We hypothesized that intramyocardial administration of naked plasmid DNA encoding VEGF121 could improve myocardial perfusion and function in a porcine model of myocardial ischemia. Yorkshire swine underwent thoracotomy and placement of an ameroid constrictor on the circumflex coronary artery. Four weeks later, pVEGF121 plasmid was administered into the ischemic myocardium. Four weeks after gene transfer, SPECT imaging demonstrated significant reduction in the ischemic area in pVEGF121-treated animals compared with controls. In the pVEGF121 group, most of the animals evolved from light ischemia to a normal perfusion. In contrast, control animals exhibited similar or impaired ischemic conditions. Our results indicate that intramyocardial gene transfer of VEGF121 as naked plasmid DNA results in significant improvement in myocardial perfusion and function.

Full Text
Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.